ActiniumActinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting
20 Apr 2023
Clinical ResultPhase 3AACRRadiation TherapyPhase 1
- Highly significant (p
- HER3 is expressed at high levels within multiple solid tumors and has been linked to poor survival and drug resistance, providing strong rationale for HER3 targeted radiotherapy in a clinical setting
NEW YORK, April 19, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announces encouraging preclinical proof of concept data at a poster presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting being held April 14 - 19, 2023 in Orlando, Florida. The poster showcased the robust anti-tumor effects of HER3-targeted radiotherapy using multiple therapeutic radionuclides in preclinical models of high unmet need malignancies.
Highlights from the AACR poster titled, "Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumorsHER3-positive solid tumors" include:
Actinium's HER3-targeted radiotherapy displayed strong anticancer activity when conjugated to either alpha-emitting Actinium-225 or beta-emitting Lutetium-177 in models of two high unmet need cancers, highlighting its therapeutic potential for HER3+ malignanciesHER3+ malignancies
HER3-ARC showed strong target engagement and efficient cellular internalization with compelling cytotoxic activity against established in vitro cellular models
A single dose of HER3-ARC, conjugated to either Actinium-225 (p
"Actinium is committed to developing targeted radiotherapies for patients with unmet needs and our program targeting HER3, a validated, pan-cancer target, is a strong representation of our R&D capabilities", said Sandesh Seth, Actinium's Chairman and CEO. "The new data from our HER3 program once again demonstrate the potent anti-tumor effect and broad utility of targeted radiotherapy in solid tumors. Building on our prior results in lung cancer models, we are excited by the highly significant reduction in tumor burden seen in ovarian cancer and colorectal cancer models, providing much improved treatment options to critical patients with poor clinical outcomes. These data also demonstrate our isotope-agnostic approach to targeted radiotherapy development enabling us to generate optimal therapies, given our strong, industry leading clinical experience with both beta and alpha therapies."
HER3 is a member of the EGFR family, a highly validated cancer target for which there are several approved therapies directed against EGFR and/or HER2. However, there are no approved therapeutics targeting HER3, which is upregulated in response to EGFR and HER2 therapies as part of acquired resistance and is associated with poor survival in multiple solid tumors including breast, colorectal, lung, ovarian and others.
The poster will be available on the presentations page of Actinium's investor relations page of its website: https://ir.actiniumpharma.com/presentations-webinars.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. Actinium's clinical pipeline is led by targeted radiotherapies that are being applied to targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a bone marrow transplant (BMT), gene therapy or adoptive cell therapy, such as CAR-T, to enable engraftment of these transplanted cells with minimal toxicities. Our lead product candidate, Iomab-B (I-131 apamistamab) has been studied in over four hundred patients, including the pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial was positive with Iomab-B meeting the primary endpoint of durable Complete Remission of 6 months with high statistical significance (phttps://www.actiniumpharma.com/.
Investors:
Hans Vitzthum
[email protected]
(617) 430-7578
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.